Kiniksa Pharmaceuticals's total assets for Q1 2026 were $825.28M, an increase of 8.07% from the previous quarter. KNSA total liabilities were $219.59M for the fiscal quarter, a 12.02% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.